Pharmacokinetic profile of the somatostatin analogue lanreotide in individuals with chronic hepatic insufficiency

Clinical Pharmacokinetics

Volumn 45, Issue 10, 2006, Pages 1003-1011

  Tomlinson, Brian ^a   Thomas, Neil G ^a   Lan, Irene W ^a   Barbanoj, Manuel ^b   Antonijoan, Rosa M ^b   Drazna, Eva ^c   Ramis, Joaquim ^d   Obach, Rosendo ^d   Peraire, Concepcíon ^d  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c CHARLES UNIVERSITY   (Czech Republic)

^d IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; SOMATOSTATIN DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LIVER FAILURE; MALE; MEAN RESIDENCE TIME; NAUSEA; PRIORITY JOURNAL; RADIOIMMUNOASSAY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STEADY STATE; VOMITING;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BLOOD PRESSURE; CHRONIC DISEASE; FEMALE; HALF-LIFE; HEPATIC INSUFFICIENCY; HUMANS; INFUSIONS, INTRAVENOUS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SOMATOSTATIN;

EID: 33748941268     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645100-00004     Document Type: Article

References (29)

1. Lightman S. Somatuline Autogel: an extended release lanreotide formulation. Hosp Med 2002 Mar; 63 (3): 162-5
2. Culler MD, Taylor JE, Moreau JP. Somatostatin receptor subtypes: targeting functional and therapeutic specificity. Ann Endocrinol (Paris) 2002 Apr; 63 (2 Pt 3): 2S5-12
3. Racine MS, Barkan AL. Somatostatin analogs in medical treatment of acromegaly. Endocrine 2003 Apr; 20 (3): 271-8
4. Caron P, Bex M, Cullen DR, et al. One-year follow-up of subjects with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf) 2004 Jun; 60 (6): 734-40
5. Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002 Jan; 87 (1): 99-104
6. Ashwell SG, Bevan JS, Edwards OM, et al. The efficacy and safety of lanreotide Autogel in subjects with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 2004 Apr; 150 (4): 473-80
7. Cannav̀o S, Squadrito S, Curt̀o L, et al. Results of a two-year treatment with slow release lanreotide in acromegaly. Horm Metab Res 2000 Jun; 32 (6): 224-9
8. Cannav̀o S, Squadrito S, Curt̀o L, et al. Effectiveness of slow-release lanreotide in previously operated and untreated subjects with GH-secreting pituitary macroadenoma. Horm Metab Res 2001 Oct; 33 (10): 618-24
9. Baldelli R, Colao A, Razzore P, et al. Two-year follow-up of acromegalic subjects treated with slow release lanreotide (30mg). J Clin Endocrinol Metab 2000 Nov; 85 (11): 4099-103
10. Ruszniewski P, Ish-Shalom S, Wymenga M, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004; 80 (4): 244-51
11. Arnold R, Wied M, Behr TH. Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract. Expert Opin Pharmacother 2002 Jun; 3 (6): 643-56
12. O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000 Feb; 88 (4): 770-6
13. Wymenga AN, Eriksson B, Salmela PI, et al. Efficacy and safety of prolonged-release lanreotide in subjects with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999 Apr; 17 (4): 1111
14. Ruszniewski P, Ducreux M, Chayvialle JA, et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 subjects. Gut 1996 Aug; 39: 279-83
15. Heron I, Thomas F, Dero M, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in subjects with acromegaly. J Clin Endocrinol Metab 1993 Mar; 76 (3): 721-7
16. Amato G, Mazziotti G, Rotondi M, et al. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in subjects with previously untreated acromegaly. Clin Endocrinol (Oxf) 2002 Jan; 56 (1): 65-71
17. Antonijoan RM, Barbanoj MJ, Cordero JA, et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy subjects. J Pharm Pharmacol 2004 Apr; 56 (4): 471-6
18. Kuhn JM, Basin C, Mollard M, et al. Pharmacokinetic study and effects on growth hormone secretion in healthy subjects of the new somatostatin analogue BIM 23014. Eur J Clin Pharmacol 1993; 45 (1): 73-7
19. Kuhn JM, Legrand A, Ruiz JM, et al. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy subjects. Br J Clin Pharmacol 1994 Sep; 38 (3): 213-9
20. Bronstein M, Musolino N, Jallad R, et al. Pharmacokinetic profile of lanreotide Autogel® in subjects with acromegaly after four deep subcutaneous injections of 60, 90 or 120mg every 28 days. Clin Endocrinol (Oxf) 2005; 63: 514-9
21. Cendros JM, Peraire C, Troconiz IF, et al. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metabolism 2005 Oct; 54 (10): 1276-81
22. Barbanoj M, Antonijoan R, Morte A, et al. Pharmacokinetics of the somatostatin analog lanreotide in subjects with severe chronic renal insufficiency. Clin Pharmacol Ther 1999 Nov; 66 (5): 485-91
23. Adedoyin A, Arns PA, Richards WO, et al. Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6. Clin Pharmacol Ther 1998 Jul; 64 (1): 8-17
24. McLean AJ, Morgan DJ. Clinical pharmacokinetics in subjects with liver disease. Clin Pharmacokinet 1991 Jul; 21: 42-69
25. Polonsky KS, Jaspan JB, Berelowith M, et al. Hepatic and renal metabolism of somatostatin-like immunoreactivity. J Clin Invest 1981 Nov; 68 (5): 1149-57
26. Sheppard M, Shapiro B, Pimstone B, et al. Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab 1979 Jan; 48 (1): 50-3
27. Ottesen LH, Flyvbjerg A, Jakobsen P, et al. The pharmacokinetics of octreotide in cirrhosis and in healthy man. J Hepatol 1997 May; 26 (5): 1018-25
28. Demotes-Mainard F, Vincon G, Amouretti M, et al. Pharmacokinetics and protein binding of cefpiramide in patients with alcoholic cirrhosis. Clin Pharmacol Ther 1991 Mar; 49 (3): 263-9
29. US Food and Drug Administration. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing labeling. Guidance for industry. Rockville (MD): Center for Drug Evaluation and Research (CDER), 2003